NSC-95397
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 551008

CAS#: 93718-83-3

Description: NSC-95397 is a novel CDC25B inhibitor, inhibiting influenza A virus replication in dose-dependent fashion. NSC95397 prevents the CtBP1-Protein Partner Interaction and CtBP1-Mediated Transcriptional Repression. NSC-95397 triggers apoptosis of tumor cells and is thus considered for the treatment of malignancy.


Price and Availability

Size Price Shipping out time Quantity
5mg USD 230 2 Weeks
10mg USD 360 2 Weeks
25mg USD 730 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-08-08. Prices are subject to change without notice.

NSC-95397, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 551008
Name: NSC-95397
CAS#: 93718-83-3
Chemical Formula: C14H14O4S2
Exact Mass: 310.0334
Molecular Weight: 310.382
Elemental Analysis: C, 54.18; H, 4.55; O, 20.62; S, 20.66


Synonym: NSC-95397; NSC95397; NSC 95397

IUPAC/Chemical Name: 2,3-Bis(2-hydroxyethylsulfanyl)naphthalene-1,4-dione

InChi Key: MAASHDQFQDDECQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H14O4S2/c15-5-7-19-13-11(17)9-3-1-2-4-10(9)12(18)14(13)20-8-6-16/h1-4,15-16H,5-8H2

SMILES Code: O=C1C(SCCO)=C(SCCO)C(C2=C1C=CC=C2)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Brenner AK, Reikvam H, Rye KP, Hagen KM, Lavecchia A, Bruserud Ø. CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors. Molecules. 2017 Mar 11;22(3). pii: E446. doi: 10.3390/molecules22030446. PubMed PMID: 28287460.

2: Jemaà M, Mischitelli M, Fezai M, Almasry M, Faggio C, Lang F. Stimulation of Suicidal Erythrocyte Death by the CDC25 Inhibitor NSC-95397. Cell Physiol Biochem. 2016;40(3-4):597-607. Epub 2016 Nov 25. PubMed PMID: 27889774.

3: Blevins MA, Kouznetsova J, Krueger AB, King R, Griner LM, Hu X, Southall N, Marugan JJ, Zhang Q, Ferrer M, Zhao R. Small Molecule, NSC95397, Inhibits the CtBP1-Protein Partner Interaction and CtBP1-Mediated Transcriptional Repression. J Biomol Screen. 2015 Jun;20(5):663-72. doi: 10.1177/1087057114561400. Epub 2014 Dec 4. PubMed PMID: 25477201; PubMed Central PMCID: PMC4486263.

4: Yang Y, Yang WS, Yu T, Yi YS, Park JG, Jeong D, Kim JH, Oh JS, Yoon K, Kim JH, Cho JY. Novel anti-inflammatory function of NSC95397 by the suppression of multiple kinases. Biochem Pharmacol. 2014 Mar 15;88(2):201-15. doi: 10.1016/j.bcp.2014.01.022. Epub 2014 Jan 25. PubMed PMID: 24468133.

5: Niisato N, Ohta M, Eaton DC, Marunaka Y. Hypotonic stress upregulates β- and γ-ENaC expression through suppression of ERK by inducing MKP-1. Am J Physiol Renal Physiol. 2012 Jul 15;303(2):F240-52. doi: 10.1152/ajprenal.00198.2011. Epub 2012 May 9. PubMed PMID: 22573375; PubMed Central PMCID: PMC3404587.

6: Liu T, Li Y, Lin K, Yin H, He B, Zheng M, Wang G. Regulation of S100A4 expression via the JAK2-STAT3 pathway in rhomboid-phenotype pulmonary arterial smooth muscle cells exposure to hypoxia. Int J Biochem Cell Biol. 2012 Aug;44(8):1337-45. doi: 10.1016/j.biocel.2012.04.017. Epub 2012 Apr 27. PubMed PMID: 22561747.

7: Dulyaninova NG, Hite KM, Zencheck WD, Scudiero DA, Almo SC, Shoemaker RH, Bresnick AR. Cysteine 81 is critical for the interaction of S100A4 and myosin-IIA. Biochemistry. 2011 Aug 23;50(33):7218-27. doi: 10.1021/bi200853y. Epub 2011 Jul 21. PubMed PMID: 21749055; PubMed Central PMCID: PMC3220277.

8: Larsson DE, Wickström M, Hassan S, Oberg K, Granberg D. The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro. Anticancer Res. 2010 Jan;30(1):149-56. PubMed PMID: 20150630.

9: Soares KM, Blackmon N, Shun TY, Shinde SN, Takyi HK, Wipf P, Lazo JS, Johnston PA. Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev Technol. 2010 Apr;8(2):152-74. doi: 10.1089/adt.2009.0247. PubMed PMID: 20070233; PubMed Central PMCID: PMC3098569.

10: Larsson DE, Hassan S, Larsson R, Oberg K, Granberg D. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines. Cancer Chemother Pharmacol. 2009 Dec;65(1):5-12. doi: 10.1007/s00280-009-0997-6. Epub 2009 Apr 19. PubMed PMID: 19381631.

11: Ko S, Lee W, Lee S, Park H. Nanosecond molecular dynamics simulations of Cdc25B and its complex with a 1,4-naphthoquinone inhibitor: implications for rational inhibitor design. J Mol Graph Model. 2008 Aug;27(1):13-9. doi: 10.1016/j.jmgm.2008.02.002. Epub 2008 Feb 16. PubMed PMID: 18359256.

12: Lambert CC. Signaling pathways in ascidian oocyte maturation: the role of cyclic AMP and follicle cells in germinal vesicle breakdown. Dev Growth Differ. 2008 Mar;50(3):181-8. doi: 10.1111/j.1440-169X.2008.00983.x. Epub 2008 Feb 27. PubMed PMID: 18312430.

13: Vogt A, McDonald PR, Tamewitz A, Sikorski RP, Wipf P, Skoko JJ 3rd, Lazo JS. A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther. 2008 Feb;7(2):330-40. doi: 10.1158/1535-7163.MCT-07-2165. Epub 2008 Feb 1. PubMed PMID: 18245669.

14: Park H, Carr BI, Li M, Ham SW. Fluorinated NSC as a Cdc25 inhibitor. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2351-4. Epub 2006 Dec 21. PubMed PMID: 17379514.

15: Larsson DE, Lövborg H, Rickardson L, Larsson R, Oberg K, Granberg D. Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines. Anticancer Res. 2006 Nov-Dec;26(6B):4125-9. PubMed PMID: 17201123.

16: Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol. 2006 Apr;18(2):185-91. Epub 2006 Feb 17. Review. PubMed PMID: 16488126.

17: Peyregne VP, Kar S, Ham SW, Wang M, Wang Z, Carr BI. Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties. Mol Cancer Ther. 2005 Apr;4(4):595-602. PubMed PMID: 15827333.

18: Melchheier I, von Montfort C, Stuhlmann D, Sies H, Klotz LO. Quinone-induced Cdc25A inhibition causes ERK-dependent connexin phosphorylation. Biochem Biophys Res Commun. 2005 Feb 25;327(4):1016-23. PubMed PMID: 15652497.

19: Rudolph J. Targeting the neighbor's pool. Mol Pharmacol. 2004 Oct;66(4):780-2. Epub 2004 Jul 16. PubMed PMID: 15258253.

20: Han Y, Shen H, Carr BI, Wipf P, Lazo JS, Pan SS. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors. J Pharmacol Exp Ther. 2004 Apr;309(1):64-70. Epub 2004 Jan 12. PubMed PMID: 14718602.